Associate Professor of Pediatrics, Dana-Farber Cancer Institute
Pediatric Hematology & Oncology
Dr. Lewis B. Silverman, MD
|
|
Give Review
Lewis Silverman is an expert in the field of Pediatric Hematology & Oncology. He went to medical school at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Lewis Silverman is a published MD. He has 59 papers published. The most current publication "Intravenous pegylated asparaginase versus intramuscular native Escherichia colil-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001):..." Lewis Silverman accepts Medicare.
Publications
- Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
- Intravenous pegylated asparaginase versus intramuscular native Escherichia colil-asparaginase in newly diagnosed childhood Acute lymphoblastic leukaemia (DFCI 05-001):...
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed Acute lymphoblastic leukemia.
- An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
- Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.
- Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell Acute lymphoblastic leukemia.
- Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
- c-Myc inhibition prevents Leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
- Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in Acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Institute All Co...
- Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk Leukemia.
- The thirteenth international childhood Acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011.
- Hematopoietic stem cell transplantation in unique pediatric populations: adolescents, infants, and children with down syndrome.
- Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
- Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood Acute lymphoblastic leukemia.
- ATF5 polymorphisms influence ATF function and response to treatment in children with childhood Acute lymphoblastic leukemia.
- Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed Acute lymphoblastic leukemia.
- The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell Acute lymphoblastic leukemia.
- Childhood T-ALL: it's time to move on.
- Neuropsychological outcomes of standard risk and high risk patients treated for Acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years po...
- Neurobehavioral side effects of corticosteroids during active treatment for Acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer ...
- The low incidence of secondary Acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for Acute lymphoblastic leukaemia: a report from the Da...
- Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive Acute lymphoblastic leukemia treated between 1995 and 2005.
- Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell Acute lymphoblastic leukemia.
- Inactivation of LEF1 in T-cell Acute lymphoblastic leukemia.
- Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed Acute lymphoblastic leukemia.
- Erwinia asparaginase after allergy to E. coli asparaginase in children with Acute lymphoblastic leukemia.
- DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood Acute lymphoblastic leukemia.
- Outcome of congenital Acute lymphoblastic leukemia treated on the Interfant-99 protocol.
- Treating childhood Leukemia without cranial irradiation.
- Clinical course and outcome in children with Acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
- High frequency of PTEN, PI3K, and AKT abnormalities in T-cell Acute lymphoblastic leukemia.
- Childhood Acute lymphoblastic leukemia: update on prognostic factors.
- H3K79 methylation profiles define murine and human MLL-AF4 Leukemias.
- Acute lymphoblastic leukemia in adolescents and young adults.
- Absence of secondary malignant neoplasms in children with high-risk Acute lymphoblastic leukemia treated with dexrazoxane.
- Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1.
- Acute lymphoblastic leukemia in infancy.
- Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in Acute lymphoblastic le...
- Outcome of treatment in children with hypodiploid Acute lymphoblastic leukemia.
- Favorable outcome for adolescents with Acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with Acute lymphoblastic leukemia.
- Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.
- Antigen-specific T-cell memory is preserved in children treated for Acute lymphoblastic leukemia.
- Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative Disease using B-cell-directed therapy.
- Activating mutations of NOTCH1 in human T cell Acute lymphoblastic leukemia.
- The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with Acute lymphoblastic leukemia.
- Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk Acute lymphoblastic leukemia: therapeutic efficacy and neuroto...
- FLT3 mutations in childhood Acute lymphoblastic leukemia.
- Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with Acute lymphoblastic leukemia at diagnosis and at relapse: implicati...
- Childhood T-cell Acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute lymphoblastic leukemia consortium experience.
- Height and weight in children treated for Acute lymphoblastic leukemia: relationship to CNS treatment.
- Gene expression signatures in MLL-rearranged T-lineage and B-precursor Acute leukemias: dominance of HOX dysregulation.
- Newly diagnosed childhood Acute lymphoblastic leukemia: update on prognostic factors and treatment.
- Childhood Leukemia: electric and magnetic fields as possible risk factors.
- Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
- MLL translocations specify a distinct gene expression profile that distinguishes a unique Leukemia.
- Treatment of childhood Acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.
- Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric Acute lymphoblastic leukaemia.
Schools
Harvard Medical School
Children39s Hospital Boston
Conditions Treated
- Acute Leukemia
- Anemia
- Hodgkin's Disease
- Non-Hodgkin's Lymphoma
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
Boston Children's Hospital -
Harvard Medical School
Hospital
-
Boston Children's Hospital -
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1033137864 | |
| NPPES Provider LastName | SILVERMAN | |
| NPPES Provider FirstName | LEWIS | |
| NPPES Provider ZIPCode | 10029 | |
| NPPES Provider State | NY | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 357.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 3.92 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033137864 |
| Last Name Of The Provider | SILVERMAN |
| First Name Of The Provider | LEWIS |
| View All |
Similar Doctors
|
|
Dr. Mary S. Huang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Sudha Parasuraman, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ilonna J. Rimm, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura K. Aguilar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachael Grace, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vijay G. Sankaran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Loretta S. Li, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven P. Margossian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeremy W. Rupon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicolas J. Llosa, MD
This Doctor is OpenDoctor Recommended.
|